Prelude Therapeutics IncNASDAQ:PRLD
- LAST PRICE3.2250
- TODAY'S CHANGE (%)-0.0850 (-2.5680%)
- Bid / Lots2.9000/ 3
- Ask / Lots3.2000/ 3
- Open / Previous Close3.2100 / 3.3100
- Day Range
- 52 Week Range
- Volume77,171
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PRLD |
|---|---|---|
| 09:37 ET | 875 | 3.21 |
| 09:42 ET | 500 | 3.2 |
| 09:46 ET | 200 | 3.24 |
| 10:15 ET | 733 | 3.25 |
| 10:20 ET | 100 | 3.27 |
| 10:36 ET | 2578 | 3.25 |
| 10:40 ET | 858 | 3.24 |
| 10:42 ET | 100 | 3.26 |
| 10:45 ET | 200 | 3.24 |
| 10:47 ET | 100 | 3.21 |
| 10:49 ET | 100 | 3.25 |
| 10:51 ET | 200 | 3.22 |
| 10:54 ET | 600 | 3.21 |
| 11:00 ET | 100 | 3.22 |
| 11:02 ET | 100 | 3.23 |
| 11:05 ET | 100 | 3.24 |
| 11:07 ET | 100 | 3.245 |
| 11:12 ET | 347 | 3.24 |
| 11:14 ET | 100 | 3.24 |
| 11:16 ET | 982 | 3.24 |
| 11:20 ET | 100 | 3.24 |
| 11:21 ET | 100 | 3.24 |
| 11:23 ET | 200 | 3.2366 |
| 11:25 ET | 212 | 3.24 |
| 11:27 ET | 100 | 3.21 |
| 11:38 ET | 400 | 3.2296 |
| 11:39 ET | 1000 | 3.2687 |
| 11:41 ET | 100 | 3.26 |
| 11:43 ET | 600 | 3.24 |
| 11:45 ET | 100 | 3.26 |
| 11:48 ET | 100 | 3.26 |
| 11:52 ET | 531 | 3.26 |
| 11:56 ET | 300 | 3.24 |
| 11:57 ET | 429 | 3.24 |
| 11:59 ET | 100 | 3.24 |
| 12:03 ET | 100 | 3.22 |
| 12:06 ET | 167 | 3.24 |
| 12:10 ET | 200 | 3.24 |
| 12:15 ET | 841 | 3.25 |
| 12:17 ET | 100 | 3.21 |
| 12:21 ET | 605 | 3.21 |
| 12:28 ET | 100 | 3.21 |
| 12:30 ET | 300 | 3.23 |
| 12:44 ET | 100 | 3.22 |
| 12:48 ET | 500 | 3.235 |
| 12:55 ET | 100 | 3.235 |
| 01:31 ET | 264 | 3.235 |
| 01:33 ET | 400 | 3.24 |
| 01:47 ET | 100 | 3.25 |
| 01:49 ET | 1397 | 3.21 |
| 02:00 ET | 537 | 3.18 |
| 02:02 ET | 645 | 3.18 |
| 02:09 ET | 900 | 3.18 |
| 02:12 ET | 350 | 3.17 |
| 02:16 ET | 200 | 3.17 |
| 02:18 ET | 100 | 3.18 |
| 02:20 ET | 400 | 3.1791 |
| 02:21 ET | 1000 | 3.17 |
| 02:23 ET | 1205 | 3.14 |
| 02:30 ET | 1200 | 3.11 |
| 02:32 ET | 2018 | 3.2 |
| 02:36 ET | 482 | 3.19 |
| 02:41 ET | 100 | 3.18 |
| 02:48 ET | 100 | 3.18 |
| 02:54 ET | 100 | 3.18 |
| 02:59 ET | 100 | 3.15 |
| 03:01 ET | 100 | 3.15 |
| 03:06 ET | 134 | 3.15 |
| 03:08 ET | 600 | 3.17 |
| 03:12 ET | 300 | 3.15 |
| 03:14 ET | 300 | 3.1583 |
| 03:15 ET | 200 | 3.16 |
| 03:17 ET | 500 | 3.15 |
| 03:19 ET | 100 | 3.1619 |
| 03:26 ET | 1191 | 3.15 |
| 03:30 ET | 1935 | 3.1403 |
| 03:32 ET | 100 | 3.14 |
| 03:35 ET | 258 | 3.15 |
| 03:37 ET | 400 | 3.15 |
| 03:44 ET | 103 | 3.14 |
| 03:48 ET | 400 | 3.14 |
| 03:50 ET | 200 | 3.1575 |
| 03:51 ET | 650 | 3.18 |
| 03:53 ET | 200 | 3.23 |
| 03:55 ET | 1796 | 3.25 |
| 03:57 ET | 877 | 3.22 |
| 04:00 ET | 21539 | 3.225 |
Nov 11, 2023
Nov 7, 2023
DJ Prelude Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 1:30PM ET on Tuesday Nov 07, 2023 by Dow Jones
1:30PM ET on Tuesday Nov 07, 2023 by Dow Jones
Nov 4, 2023
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Prelude Therapeutics Inc | 176.8M | -1.5x | --- |
Astria Therapeutics Inc | 172.4M | -2.2x | --- |
INmune Bio Inc | 173.2M | -6.3x | --- |
Theseus Pharmaceuticals Inc | 170.7M | -2.9x | --- |
Invivyd Inc | 169.6M | -1.0x | --- |
Merrimack Pharmaceuticals Inc | 184.7M | -127.3x | --- |
Company Information
Prelude Therapeutics Inc. is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. The Company’s product candidates include PRT1419, PRT2527, PRT3789, and PRT3645. PRT1419 is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. PRT2527 is a potent and highly selective CDK9 inhibitor. PRT2527 treatment demonstrated robust efficacy in both hematological malignancies and solid tumor models with MYC. PRT3645 is a next-generation CDK4/6 inhibitor. PRT3789 is an IV-administered SMARCA2 degrader. Its pipeline consists of multiple distinct programs spanning methyltransferases, kinases, protein-protein interactions, and targeted protein degraders.
Contact Information
- Headquarters
- 200 Powder Mill RoadWILMINGTON, DE, United States 19803
- Phone
- 302-547-3768
- Fax
- 302-658-3989
Executives
- Independent Chairman of the Board
- Paul Friedman
- President, Chief Medical Officer
- Jane Huang
- Chief Executive Officer, Founder, Director
- Krishna Vaddi
- Chief Financial Officer
- Laurent Chardonnet
- Executive Vice President, Head of Chemistry
- Andrew Combs
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $176.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 54.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.17 |
Book Value | $4.08 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
